Researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer

May 29, 2012

GW Researchers, Jeffrey M. Bethony, Ph.D., associate professor of Microbiology, Immunology, and Tropical Medicine, and Paul Brindley, Ph.D., professor of Microbiology, Immunology, and Tropical Medicine at GW School of Medicine and Health Sciences, along with colleagues from Khon Kaen University in Thailand have determined that plasma Interleukin-6 (IL-6) levels are an sensitive and specific biomarker for the detection of the advanced bile duct fibrosis and bile duct cancer that comes from chronic infection with the Asian Liver Fluke (Opisthorchis viverrini). The research, titled, "Elevated Plasma IL-6 Associates with Increased Risk of Advanced Fibrosis and Cholangiocarcinoma in Individuals Infected by Opisthorchis viverrini," was recently published in the journal, PLoS Neglected Tropical Diseases.

This discovery is a critical advance for the Northeastern (Isaan) region of Thailand and other areas of Southeast Asia, where an estimated 10 million people are currently infected with Asian , which is the leading cause of cancer in the region. This food-borne parasite encysts in the fins, skin, and of fish and infection occurs when people ingest this raw or uncooked fish. While the infection can be cured by chemotherapy, environmental and cultural factors of the region strongly favors rapid reinfection, with as a common outcome. Northeastern Thailand has the highest levels bile duct cancer in the world. The determination that plasma IL-6 levels are associated with bile duct fibrosis (a precursor state to bile duct cancer) and early bile duct cancer were done by examining participants in the Khon Kaen Cohort, the largest cancer cohort of its type in the world, and an NIH sponsored project in collaboration with George Washington University and Khon Kaen University. In this study, researchers visited nearly 4,000 individuals resident in rural areas of Thailand, where the parasite is endemic to conduct ultrasound studies to detect advanced bile duct fibrosis and early bile duct cancer and then link the ultrasound results with levels of plasma IL-6. This research was done in collaboration with Drs. Banchob Sripa, Bandit Thinkhamrop, Eimorn Mairiang, and Thewarach Laha from the Khon Kaen University School of Medicine and School of Public Health.

As a result of the identifying this biomarker, the Thai Ministry of Public Health has implemented testing for levels of plasma IL-6 for individuals between 20 and 60 in endemic regions of Isaan Thailand to identify individuals at risk for bile duct cancer. Through this test, it is hoped that bile duct cancer can be detected earlier and at a more treatable stage.

"Typically, bile duct cancer has a late presentation, and so a very high mortality rate. Now that we've identified the IL-6 , our hope is that earlier detection is possible and earlier treatment saves more lives," said Jeffrey M. Bethony, Ph.D., associate professor of Microbiology, Immunology, and Tropical Medicine at the GW School of Medicine and Health Sciences (SMHS).

In collaboration with Dr. Jason Mulvenna of the Queensland Institute of Medical Research in Brisbane Australia, the researchers are also using quantitative proteomics approaches to identify biomarkers that could be used in an even more sensitive and specific test for the early detection of this infection-associated bile duct cancer. The current discovery was possible through funding from an RO1 grant (R01CA155297-01) from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

Explore further: Scientists make breakthrough in study on bile duct cancer with discovery of new gene mutations

Related Stories

Scientists make breakthrough in study on bile duct cancer with discovery of new gene mutations

May 9, 2012
(Medical Xpress) -- A combined team of scientists from Singapore and Thailand has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. Using the latest genomic technologies, ...

Novel gene mutations associated with bile duct cancer

January 18, 2012
Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited. ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.